Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: RNS60 125 ml, RNS60 250 ml, Interferon beta 1a; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis (MS)
Interventions: Alemtuzumab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: MRI; Other
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 58 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions: ANK-700, Placebo; Drug
Lead sponsor: Anokion SA; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Transcranial Direct Current Stimulation, Sham transcranial direct current stimulation; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions: BIIB033, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Centennial, Colorado

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5,448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Intermittent fasting; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Ozanimod placebo, Interferon beta-1a, Interferon beta-1a placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more

Conditions: Multiple Sclerosis
Interventions: Rebif® New Formulation (RNF) using RebiSmartTM; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 930 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 56
States / cities: Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Remibrutinib, Ocrelizumab (US); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Sclerosis
Interventions: Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 35
States / cities: Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions: ACTH, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Teriflunomide; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BG00012, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 39
States / cities: Gilbert, Arizona • Phoenix, Arizona • San Francisco, California + 36 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide (HMR1726); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 4
States / cities: Maitland, Florida • Fort Wayne, Indiana • Detroit, Michigan + 1 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more

Search by objective public record fields.

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

Maximizing Outcome of Multiple Sclerosis Transplantation

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

Intermittent Fasting in Multiple Sclerosis

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

ACTH in Progressive Forms of MS

Mechanistic Studies of Teriflunomide in RRMS

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis